B+
Bull case
30%
Probability
Target price
$195.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
BDX
Becton Dickinson andBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$183.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$160.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+66.0
Score
AI commentary
News tone is positive following the company-reported beat and guidance increase. However, the Aug. 7 price action was essentially flat, and post-print analyst revisions or target changes remain unavailable. Social, options, short-interest, and employee-sentiment data are unavailable; confidence remains moderate rather than high.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
Forward visibility is limited, so this memo should be read as a lower-conviction monitoring view rather than a catalyst-driven call.; no forward-looking company-specific catalyst is supported by primary-source evidence; high-coverage catalyst set is still too generic or cadence-driven; high-coverage report lacks a dated company-specific catalyst beyond generic cadence; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-08-06eventQ3 FY26 beat and raised full-year outlookMedium impact
BD reported $4.98 billion of revenue, 4.4% FXN growth, adjusted EPS of $3.23, and strong year-to-date cash generation; management said revenue should reach the high end of its range and raised the adjusted EPS guidance midpoint [#SEC-8K-2026-08-06].
2026-08-06catalystConcrete New BD product and platform milestonesHigh impact
The August 6 company release identified specific execution milestones: a Vizient contract for CentroVena One, an EMS collaboration for Vystra-based semaglutide delivery, and the Elyra Thulium Fiber Laser launch. These provide dated company-specific evidence for longer-term focused MedTech execution [#SEC-8K-2026-08-06].
2026-08-07catalystMuted post-print follow-throughMedium impact
The Aug. 7 anchor was $176.86 and the market snapshot showed shares essentially flat versus the prior close, so the Q3 beat and guidance raise have not yet produced clear sustained price follow-through. Analyst revisions remain unavailable.
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology